Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

Search results for "ORPHAN DRUG|Designated/Withdrawn|Treatment of hemophilia A" in comments (approximate match)

Showing 1 - 2 of 2 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT

P89DR4NY54

Subunit 1 (1313) Similarity Search Subunit 2 (684) Similarity Search

Sequence Search

Subunit 1 (1313) Similarity Search Subunit 2 (684) Similarity Search

Status:

US Approved Rx (2007)

Source:

BLA103332

(2007)

Source URL:

https://www.fda.gov/media/113210/download

First approved in 1992

Source:

BLA103375

Source URL:

https://www.fda.gov/media/113210/download

Class:

PROTEIN

BEFOVACIMAB

8FFQ0L4R3B

Subunit 1 (442) Similarity Search Subunit 2 (442) Similarity Search Subunit 3 (212) Similarity Search Subunit 4 (212) Similarity Search

Sequence Search

Subunit 1 (442) Similarity Search Subunit 2 (442) Similarity Search Subunit 3 (212) Similarity Search Subunit 4 (212) Similarity Search

Status:

Investigational

Source:

NCT03481946: Phase 1 Interventional Completed Hemophilia A; Hemophilia B

(2018)

Source URL:

https://clinicaltrials.gov/ct2/show/NCT03481946

Class:

PROTEIN

Protein

ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT

Protein

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1